By Stephen Nakrosis
AN2 Therapeutics said it was planning to meet with the U.S. Food and Drug Administration to discuss a development path for epetraborole, a treatment of non-tuberculous mycobacterial lung disease.
The company said it will seek an End-of-Phase 2 meeting with the FDA in the first half of next year, and expects to leverage insights from Phase 2 results to evaluate potential reinitiation of a Phase 3 study. AN2 also said it will seek to align with the agency on a statistical analysis plan for 97 patients who completed six months of treatment in a trial which was halted August. The company said it expects to release top-line Phase 3 data from these patients in mid-2025, subject to the timing of discussions with the FDA.
Eric Easom, the company's co-founder, chairman, president and chief executive officer, said recent data analysis indicate that epetraborole may provide clinical improvement in patients with treatment-refractory MAC lung disease.
The company said epetraborole is the first drug candidate with statistically favorable patient reported outcome-based improvement in a treatment-refractory Mycobacterium avium Complex population.
AN2 also said it is continuing to advance its pipeline of boron-based compounds to address unmet patient needs.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 13, 2024 17:06 ET (22:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.